BiotechTube

Secukinumab 150 milligram [Cosentyx]

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Axial Spondyloarthritis

Conditions

Axial Spondyloarthritis, Ankylosing Spondylitis

Trial Timeline

Jan 15, 2019 → Feb 1, 2021

NCT ID
NCT03639740

About Secukinumab 150 milligram [Cosentyx]

Secukinumab 150 milligram [Cosentyx] is a approved stage product being developed by Novartis for Axial Spondyloarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03639740. Target conditions include Axial Spondyloarthritis, Ankylosing Spondylitis.

What happened to similar drugs?

5 of 20 similar drugs in Axial Spondyloarthritis were approved

Approved (5) Terminated (1) Active (15)
✅AdalimumabAbbVieApproved
✅Secukinumab + Placebo + SecukinumabNovartisApproved
✅etanercept + etanercept + placeboPfizerApproved
✅Tofacitinib 5 MGPfizerApproved
✅Certolizumab PegolUCBApproved
🔄Brodalumab + PlaceboKyowa KirinPhase 3
🔄Ixekizumab + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03639740ApprovedUNKNOWN

Competing Products

20 competing products in Axial Spondyloarthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
Brodalumab + PlaceboKyowa KirinPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
SHR-1314Jiangsu Hengrui MedicinePhase 1
29
UpadacitinibAbbViePre-clinical
33
AdalimumabAbbVieApproved
35
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
40
adalimumab + PlaceboAbbViePhase 3
40
TreatmentMerckPre-clinical
66
GolimumabMerckPhase 3
40
Tulisokibart + PlaceboMerckPhase 2
42
secukinumabNovartisPre-clinical
26
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab + Secukinumab and PlaceboNovartisPhase 3
40
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
40
Brodalumab 210 mg + PlaceboAmgenPhase 2
27
Etanercept 25mg + SulfasalazinePfizerPhase 2
31